



Title	Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions, and chemical reagents
Author(s)	Kariwa, Hiroaki; Fujii, Nobuhiro; Takashima, Ikuo
Citation	Japanese Journal of Veterinary Research, 52(3), 105-112
Issue Date	2004-11
DOI	10.14943/jjvr.52.3.105
Doc URL	http://hdl.handle.net/2115/10516
Type	bulletin (article)
File Information	52(3)_105-112.pdf



[Instructions for use](#)

Inactivation of SARS coronavirus by means of povidone-iodine, physical conditions, and chemical reagents

Hiroaki Kariwa*, Nobuhiro Fujii[†], and Ikuo Takashima*

(Accepted for publication : September 28, 2004)

Abstract

The efficacy of several povidone-iodine (PVP-I) products, a number of other chemical agents, and various physical conditions were evaluated for their ability to inactivate the severe acute respiratory syndrome coronavirus (SARS-CoV). Treatment of SARS-CoV with PVP-I products for 2 min reduced the virus infectivity from 1.17×10^6 TCID₅₀/ml to below the detectable level. The efficacy of 70% ethanol was equivalent to that of PVP-I products. Fixation of SARS-CoV-infected Vero E6 cells with a fixative including formalin, glutaraldehyde, methanol, and acetone for 5 min or longer eliminated all infectivity. Heating the virus at 56°C for 5 min dramatically reduced the infectivity of the virus from 2.6×10^7 to 40 TCID₅₀/ml, whereas heating the virus for 60 min or longer eliminated all infectivity. Irradiation with ultraviolet light at $134 \mu\text{W}/\text{cm}^2$ for 15 min reduced the infectivity from 3.8×10^7 to 180 TCID₅₀/ml; however, prolonged irradiation (60 min) failed to eliminate the remaining virus, leaving 18.8 TCID₅₀/ml. We believe that these findings will be useful for the implementation of infection control measures against SARS, and for the establishment of effective guidelines for the prevention of SARS outbreaks.

Key words : coronavirus, disinfection, inactivation, infection control, povidone-iodine, SARS, Severe acute respiratory syndrome.

Introduction

Severe acute respiratory syndrome (SARS) was first reported as an atypical pneumonia in Gangdong, China, in November, 2002¹³⁾. The epidemic expanded rapidly to

26 regions and countries^{14, 15, 16)} and by the end of July 2003, 8,098 probable cases had been reported and more than 774 people had died⁹⁾. Although the epidemic seemed to be controlled during the summer of 2003, laboratory-associated infections appeared in Singapore

*Laboratory of Public Health, Graduate School of Veterinary Medicine, Hokkaido University, Sapporo 060-0818, Japan

[†]Department of Microbiology, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Japan

in September 2003¹⁸⁾, in Taiwan in December 2003¹⁹⁾, and in Beijing in April 2004²⁰⁾. At the end of 2003, a new series of probable SARS cases, which may have been unrelated to laboratory sources of infection, re-emerged in Gangdong²¹⁾. Therefore, it must be considered possible that SARS outbreaks could start at any time, anywhere in the world.

In March 2003, a distinct coronavirus was identified as the causative agent of SARS and designated as SARS-coronavirus (SARS-CoV)^{2,7,8)}. SARS-CoV is an enveloped virus with a single positive-stranded RNA genome, for which the genome organization has been characterized¹¹⁾. Because SARS-CoV was isolated or identified in Himalayan palm civets (*Paguma larvata*) and raccoon dogs (*Nyctereutes procyonoides*), SARS appears to have a zoonotic origin⁴⁾. However, the definitive animal reservoir for human cases of SARS-CoV has not yet been determined, and no effective vaccines or antiviral drugs have yet been developed.

Given this situation, the initial infection control effort in healthcare, home, and community settings is crucially important to minimize the occurrence and spread of epidemics. The WHO laboratory network for SARS diagnosis reported preliminary data concerning the stability and resistance of the virus¹⁷⁾. The virus seems to be susceptible to inactivation by heating and exposure to organic chemicals that disrupt the virus envelope, such as acetone and ethanol, as well as fixatives such as formalin^{10,17)}. However, additional information on inactivation of SARS-CoV is imperative for the establishment of effective infection control protocols in a variety of settings. As several SARS outbreaks may have originated from laboratories^{18,19,20)}, the guidelines for handling the virus in the laboratory must be established according to accurate information on the stability of SARS-CoV.

Povidone-iodine (PVP-I) products have been used for the disinfection of various bacteria and viruses for years because of their strong bactericidal and antiviral activities^{5,6)}. If reliable data confirm the efficacy of PVP-I for the elimination of SARS-CoV infectivity, these products will become extremely useful for the disinfection of the virus in various settings.

In this paper we evaluated the antiviral efficacy of PVP-I against SARS-CoV; we also evaluated the antiviral efficacy of various physical and chemical inactivation conditions.

Materials and methods

Virus and cells

The Hanoi strain of SARS-CoV was kindly provided by Dr. Koichi Morita, of Nagasaki University. The virus was propagated in Vero E6 cells, cultured in minimum essential medium (MEM), containing 10% fetal bovine serum. Virus stocks were prepared by collecting the culture supernatants from infected cells 48h after infection, centrifuging the fluid at 2,000 rpm for 10 min, and storing the clarified supernatants at -80°C until use.

Evaluation of the antiviral activity of PVP-I products against SARS-CoV

Aliquots of stock virus (0.1ml) were mixed with an equal volume of various PVP-I products (Meiji Seika Kaisha, Ltd., Tokyo), including Isodine[®] solution, Isodine Scrub[®], Isodine Palm[®], Isodine Gargle[®], and Isodine Nodo Fresh[®]. The mixtures were incubated for 1 min at room temperature and then diluted ten-fold with sodium thiosulphate (0.5%) to neutralize the cytotoxicity and antiviral activity of PVP-I. The mixtures were serially diluted in MEM and 0.1-ml aliquots were inoculated onto Vero E6 monolayers in 96-well plates. The cells were incubated for 48h in a CO₂ incubator and the cytopathic effect (CPE)

was observed under a microscope. The 50% tissue culture infectivity dose (TCID₅₀/ml) remaining in the virus-disinfectant mixture was determined by the method of Reed and Muench. The antiviral efficacy of ethanol (70%) was evaluated in the same manner, except for the addition of MEM to dilute the mixture, rather than sodium thiosulphate.

Inactivation of infectivity of SARS-CoV-infected Vero E6 cells by chemical reagents

Vero E6 cells grown in a 75-cm² flask were infected with SARS-CoV and cultured for 48h in a CO₂ incubator. By 48h post-infection, most of the cells had detached from the substrate, due to the development of strong CPE. These floating cells were collected with the medium and centrifuged at 2,000 rpm for 10 min. The cell pellet was resuspended in 2 ml of MEM and 0.5-ml aliquots of this cell suspension were distributed into cryogenic vials. After an additional centrifugation, the supernatant was removed and the cell pellets were stored at -80°C to be used as the stock of infected Vero E6 cells.

The infected cells were thawed and suspended in 100% acetone, 100% methanol, 3.5% paraformaldehyde, or 2.5% glutaraldehyde for various times. The cells suspended in acetone were held at -10°C in a freezer. The cells suspended in the other reagents were held at room temperature. After the treatment, the cells were collected by centrifugation, washed with phosphate buffered saline (PBS), and suspended in 1 ml MEM. The serially diluted cells were inoculated onto Vero E6 cells grown in flat-bottom 96-well plates, and the remaining infectivity was determined by the TCID₅₀ method. Normal uninfected Vero E6 cells were also incubated with the fixatives and inoculated onto Vero E6 monolayers to see the cytotoxicity caused by the fixed cells.

Physical inactivation of SARS-CoV

For the evaluation of heat-inactivation, aliquots of the virus stock were placed in 50-ml tubes and heated at 56°C in a water bath for various times. The temperature in the tubes was monitored with a thermometer placed in the same amount of MEM in a separate tube. To evaluate the efficacy of ultraviolet (UV) irradiation, 2-ml aliquots of stock virus were placed in open 3-cm plastic Petri dishes, positioned under the UV-light source in a biosafety cabinet, and irradiated with 134 μW/cm² for various times. The treated virus stocks were serially diluted in U-bottom 96-well plates, and 100-μl aliquots of diluted virus were inoculated onto monolayers of Vero E6 cells in 96-well plates and cultured for 48h in a CO₂ incubator. The CPE was observed under a microscope.

Results

Efficacy of PVP-I on SARS-CoV

We tested the efficacy of several PVP-I products for the inactivation of SARS-CoV, including Isodine[®], Isodine Scrub[®], Isodine Gargle[®], Isodine Palm[®], and Isodine Nodo Fresh[®], all of which are used for disinfection in various settings. Treatment of SARS-CoV for 1 min with Isodine Scrub[®], Isodine Palm[®], and Isodine Nodo Fresh[®] strongly reduced the virus infectivity from 1.17x 10⁶ TCID₅₀/ml to below the detection limit, <40 to <160 (Table 1). In contrast, 1-min treatment with Isodine[®] and Isodine Gargle[®] did not completely eliminate the virus infectivity; the reduction rates were 8.1x 10⁻⁵ and 1.6x 10⁻⁴, respectively. However, treatment with all the PVP-I products for 2 min completely inactivated the virus. The treatment of 70% ethanol for 1 min also reduced the virus infectivity under the detectable level (<10). These results strongly indicate that PVP-I products and 70% ethanol are effective for the inactivation of SARS-CoV.

Table 1 . Efficacy of povidone iodine products to SARS-Coronavirus

Reagent or treatment	Final povidone iodine concentration (%)	Virus titer after treatment (TCID ₅₀ /ml)	
		60sec	120sec
Control	0	1.17x10 ⁶	N. D. [#]
Isodine [®]	1	95.1	<80
Isodine Gargle [®]	0.47	190	<40
Isodine Scrub [®]	1	<160	N. D.
Isodine Palm [®]	0.25	<80	N. D.
Isodine Nodo Fresh [®]	0.23	<40	N. D.
Ethanol (final 35%)	—	<10	N. D.

[#]Not done

Table 2 . Inactivation of Vero E6 cells infected with SARS-Coronavirus by various reagent

Reagent	Infectivity of cells infected with SARS-CoV after treatment with reagents (TCID ₅₀ /ml)					
	0 min	5 min	15min	30min	60min	90min
Methanol	2.1x10 ⁷	N.D.	N.D.	<20	<20	<20
Acetone	1.3x10 ⁷	<20	<20	<20	<20	N.D.
2.5% Glutaraldehyde	2.2x10 ⁶	<160	<80	<80	<80	N.D.
3.5% Paraformaldehyde	1.6x10 ⁶	<320	<320	<320	<320	N.D.

Fixation of cells infected with SARS-CoV by chemical reagents

To determine the stability of SARS-CoV treated with several chemical reagents usually used as laboratory fixatives, Vero E6 cells infected with SARS-CoV were suspended in fixatives including formalin, glutaraldehyde, methanol, and acetone. The cells were treated with the fixatives, washed with PBS, and overlaid onto Vero E6 monolayers to evaluate the remaining infectivity. After treatment with any of the fixatives for 5 min or longer, no infectivity remained in the cells (Table 2). Therefore, SARS-CoV infected cells can be effectively inactivated by these chemical reagents.

Physical inactivation of SARS-CoV

We tested the resistance of SARS-CoV to physical treatments such as heating and UV irradiation. Aliquots of virus were heated at 56°C for various times and the kinetics of vi-

rus inactivation were analyzed. Heating for 5 min rapidly inactivated the virus infectivity from 2.6x 10⁷ to 40 TCID₅₀/ml (Fig. 1). Only low infectivity (<10 TCID₅₀/ml) remained after heating for 30 min. After 60-min and 90-min treatments with heat, no virus infectivity was detected. When SARS-CoV was irradiated under normal biosafety cabinet UV lights, the virus titer was reduced from 3.8x 10⁷ to 180 TCID₅₀/ml in 15 min, but the virus was still detected (18.8 TCID₅₀/ml), even after 60min of irradiation (Fig. 2). These results indicate that SARS-CoV is relatively resistant to UV irradiation.

Discussion

PVP-I has been widely used in hospitals and households for years because of its wide spectrum of strong antiseptic and antiviral activities. Although it is generally believed that PVP-I would also be effective against SARS-CoV, little information concerning the




Figure 1. Kinetics of SARS-CoV inactivation by heating. Aliquots of SARS-CoV were heated in a 56°C water bath for the indicated times. The heated virus aliquots were serially diluted and inoculated onto monolayers of Vero E6 grown in 96-well plates. After incubation for 48h, the cytopathic effect in the cells was observed and the infectivity was determined by the TCID₅₀ method.

actual inactivation of SARS-CoV by PVP-I is available. We tested the efficacy of several PVP-I products, including Isodine[®], Isodine Scrub[®], Isodine Palm[®], Isodine Gargle[®], and Isodine Nodo Fresh[®], all of which cover a variety of disinfection applications; these applications include disinfecting medical instruments and skin, as well as hand-washing, gargling, and spraying the throat. The results clearly indicate that all the PVP-I products tested have strong virucidal activities against SARS-CoV. PVP-I products also inactivate infectivity of mouse hepatitis virus (MHV), which is one of the member of coronaviruses²²⁾. SARS-CoV may be more resistant to PVP-I than murine coronavirus since Isodine Nodo Fresh[®] did not inactivate the infectivity of SARS-CoV in 30 second (data not shown) but did inactivate the infectivity of MHV in 5 second²²⁾. Previous research has indicated that




Figure 2. Kinetics of SARS-CoV inactivation by UV-irradiation. Aliquots of SARS-CoV were irradiated with UV light for the indicated times. The irradiated virus aliquots were serially diluted and inoculated onto monolayers of Vero E6 grown in 96-well plates. After incubation for 48h, the cytopathic effect in the cells was observed and the infectivity was determined by the TCID₅₀ method.

PVP-I is effective in the reduction of the absenteeism rate in middle schools, in which gargling with PVP-I was encouraged during the peak season for common colds and influenza¹²⁾. Because SARS-CoV is believed to be transmitted mainly through the airborne route²³⁾, PVP-I products for gargling and spraying the throat may have a prophylactic effect on SARS during outbreaks. Since the virus is also shed into feces and urine^{1,24)}, and is stable in excreta for several days³⁾, scrubbing hands with PVP-I may be effective in hospitals and households, especially after contact with SARS patients and after handling the clothes or linen of the patients.

Knowing the measures that are required for inactivating the virus in the laboratory is also essential; this is because SARS of laboratory origin has been reported. Chemical reagents, heating, and UV-irradiation are the common means of inactivating pathogens. SARS-CoV infected cells were effectively inac-

tivated by treatment with cold acetone, methanol, formalin, and glutaraldehyde for 5 min or longer. Therefore, infected cells can be safely handled after fixation with these common reagents. The results of indirect fluorescent antibody assays (IFA) indicated that the antigenicity of SARS-CoV in infected cells is restored after treatment with acetone and methanol (data not shown). SARS-CoV was completely inactivated by heating at 56°C for 60 min or longer. The virus nucleocapsid protein was detected in the supernatant of infected cells by Western immunoblotting after heating at 56°C for 90 min (data not shown). Therefore, prolonged heating would be a useful method of safely preparing samples for laboratory diagnostic tests. Residues of virus on laboratory benches can be inactivated by UV-irradiation, but the efficacy is incomplete. The combination of spraying and wiping the bench with 70% ethanol, followed by UV-irradiation may completely inactivate any virus on the bench.

Outbreaks of SARS can occur anywhere in the world because virus stocks are now stored in a number of laboratories, in many countries. We believe that the results of this study will be useful in the control of SARS, and for establishing guidelines for the safe handling of live virus in the laboratory, thus preventing SARS outbreaks of laboratory origin.

Acknowledgments

We thank Dr. Koich Morita for kindly providing the Hanoi strain of SARS-CoV. This work was supported by Grant of 21st Century COE Program, "Program of Excellence for Zoonosis Control", Ministry of Education, Science, Sports and Culture.

References

1. Chan, K. H., Poon, L. L., Cheng, V. C., Guan, Y., Hung, I. F., Kong, J., Yam, L. Y., Seto, W. H., Yuen, K. Y., Peiris, J. S. 2004. Detection of SARS coronavirus in patients with suspected SARS. *Emerg. Infect. Dis.*, 10:294-299.
2. Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H. R., Becker, S., Rabenau, H., Panning, M., Kolesnikova, L., Fouchier, R. A., Berger, A., Burguiere, A. M., Cinatl, J., Eickmann, M., Escriou, N., Grywna, K., Kramme, S., Manuguerra, J. C., Muller, S., Rickerts, V., Sturmer, M., Vieth, S., Klenk, H. D., Osterhaus, A. D., Schmitz, H., Doerr, H. W. 2003. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. *N. Engl. J. Med.*, 348:1967-1976.
3. Duan, S. M., Zhao, X. S., Wen, R. F., Huang, J. J., Pi, G. H., Zhang, S. X., Han, J., Bi, S. L., Ruan, L., Dong, X. P., SARS Research Team. 2003. Stability of SARS coronavirus in human specimens and environment and its sensitivity to heating and UV irradiation. *Biomed. Environ. Sci.*, 16:246-255.
4. Guan, Y., Zheng, B. J., He, Y. Q., Liu, X. L., Zhuang, Z. X., Cheung, C. L., Luo, S. W., Li, P. H., Zhang, L. J., Guan, Y. J., Butt, K. M., Wong, K. L., Chan, K. W., Lim, W., Shortridge, K. F., Yuen, K. Y., Peiris, J. S., Poon, L. L. 2003. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. *Science*, 302:276-278.
5. Haley, C. E., Marling-Cason, M., Smith, J. W., Luby, J. P., Mackowiak, P. A. 1985. Bactericidal activity of antiseptics against methicillin-resistant *Staphylococcus aureus*. *J. Clin. Microbiol.*, 21:991-992.
6. Kawana, R., Kitamura, T., Nakagomi, O., Matsumoto, I., Arita, M., Yoshihara, N., Yanagi, K., Yamada, A., Morita, O.,

- Yoshida, Y., Furuya, Y., Chiba, S. 1997. Inactivation of human viruses by povidone-iodine in comparison with other antiseptics. *Dermatology*, 195 Suppl. 2:29-35.
7. Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., Tong, S., Urbani, C., Comer, J. A., Lim, W., Rollin, P. E., Dowell, S. F., Ling, A. E., Humphrey, C. D., Shieh, W. J., Guarner, J., Paddock, C. D., Rota, P., Fields, B., DeRisi, J., Yang, J. Y., Cox, N., Hughes, J. M., LeDuc, J. W., Bellini, W. J., Anderson, L. J., SARS Working Group. 2003. A novel coronavirus associated with severe acute respiratory syndrome. *N. Engl. J. Med.*, 348: 1953-1966.
 8. Peiris, J. S., Lai, S. T., Poon, L. L., Guan, Y., Yam, L. Y., Lim, W., Nicholls, J., Yee, W. K., Yan, W. W., Cheung, M. T., Cheng, V. C., Chan, K. H., Tsang, D. N., Yung, R. W., Ng, T. K., Yuen, K. Y., SARS study group. 2003. Coronavirus as a possible cause of severe acute respiratory syndrome. *Lancet*, 361: 1319-1325.
 9. Poutanen, S. M., Low, D. E., Henry, B., Finkelstein, S., Rose, D., Green, K., Tellier, R., Draker, R., Adachi, D., Ayers, M., Chan, A. K., Skowronski, D. M., Salit, I., Simor, A. E., Slutsky, A. S., Doyle, P. W., Krajden, M., Petric, M., Brunham, R. C., McGeer, A. J., National Microbiology Laboratory, Canada, Canadian Severe Acute Respiratory Syndrome Study Team. 2003. Identification of Severe Acute Respiratory Syndrome in Canada. *N. Engl. J. Med.*, 348:1995-2005.
 10. Rabenau, H. F., Cinatl, J., Morgenstern, B., Bauer, G., Preiser, W., Doerr, H. W. 2004. Stability and inactivation of SARS coronavirus. *Med. Microbiol. Immunol (Berl)*. (from E-publishing).
 11. Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., Penaranda, S., Bankamp, B., Maher, K., Chen, M. H., Tong, S., Tamin, A., Lowe, L., Frace, M., DeRisi, J. L., Chen, Q., Wang, D., Erdman, D. D., Peret, T. C., Burns, C., Ksiazek, T. G., Rollin, P. E., Sanchez, A., Liffick, S., Holloway, B., Limor, J., McCaustland, K., Olsen-Rasmussen, M., Fouchier, R., Gunther, S., Osterhaus, A. D., Drosten, C., Pallansch, M. A., Anderson, L. J., Bellini, W. J. 2003. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. *Science*, 300:1394-1399.
 12. Shiraishi, T., Nakagawa, Y. 2002. Evaluation of the bactericidal activity of povidone-iodine and commercially available gargle preparations. *Dermatology*, 204 Suppl. 1:37-41.
 13. World Health Organization. 2003. Acute respiratory syndrome, China. *Wkly. Epidemiol. Rec.*, 78:41.
 14. World Health Organization. 2003. Acute respiratory syndrome China, Hong Kong Special Administrative Region of China, and Viet Nam. China. *Wkly. Epidemiol. Rec.*, 78:73-74.
 15. World Health Organization. 2003. Severe acute respiratory syndrome (SARS). *Wkly. Epidemiol. Rec.*, 78:181-183.
 16. World Health Organization. 2003. Severe acute respiratory syndrome (SARS): over 100 days into the outbreak. *Wkly. Epidemiol. Rec.*, 78:217-220.
 17. World Health Organization. 2003. First data on stability and resistance of SARS coronavirus compiled by members of WHO laboratory network. Available from URL : http://www.who.int/csr/sars/survival_2003_05_04/en/index.html
 18. World Health Organization. 2003. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003. Available from URL : <http://>

- www.who.int/csr/sars/country/table_2003_09_23/en/*
19. World Health Organization. 2003. Severe acute respiratory syndrome (SARS) in Singapore . 2003 September . Available from URL: *http://www.who.int/csr/don/2003_09_10/en/*
 20. World Health Organization. Confirmed SARS case in research laboratory in Taiwan. 2003 December. Available from URL : *http://www.who.int/csr/sars/docs/press-releases/tw_17122003.asp*
 21. World Health Organization. Update 4: Review of probable and laboratory-confirmed SARS cases in southern China. Available from URL : *http://www.who.int/csr/don/2004_01_27/en/*
 22. Taguchi, F., Riku, S., Shimizu, M. 2003. Antiviral activity of povidone iodine products to murine coronavirus. *Jpn. J. Chemotherapy*, 51: 583-584. In Japanese.
 23. Yu, I. T., Li, Y., Wong, T. W., Tam, W., Chan, A. T., Lee, J. H., Leung, D. Y., Ho, T. 2004. Evidence of airborne transmission of the severe acute respiratory syndrome virus. *N. Engl. J. Med.*, 350:1731-1739.
 24. Yam WC, Chan KH, Poon LL, Guan Y, Yuen KY, Seto WH, et al. 2003. Evaluation of reverse transcription-PCR assays for rapid diagnosis of severe acute respiratory syndrome associated with a novel coronavirus. *J Clin Microbiol.*, 41:4521-4524.